Peptide Association
List Your Practice
Daily Peptide News

Latest Peptide News & Research

Breaking research, regulatory updates, and industry developments in the world of peptide science. Updated daily.

Updated today at 6:01 PM UTC

ResearchMedium

More Autophagy Reduces Toxin-Induced Kidney Failure in Mice

New preclinical research demonstrates that enhancing autophagic flux can protect aging mice from acute kidney injury induced by toxic stress, a vulnerability not present in younger subjects. The findings highlight autophagy as a mechanistic target with potential therapeutic relevance, including for peptide-based compounds that modulate cellular repair and cytoprotective pathways. This research adds to the growing body of evidence supporting autophagy-enhancing strategies in age-related organ protection.

BPC-157
Lifespan.ioJuly 23, 2026
4 min read
LongevityMedium

Fight Aging! Newsletter, July 27th 2026

The Fight Aging! newsletter covers developments in longevity science and aging research, including topics relevant to cellular maintenance mechanisms and age-related disease intervention. This edition addresses neuromuscular junction function, immune system aging, and bone tissue maintenance, areas of ongoing interest within the peptide therapy and longevity research communities. Researchers and clinicians tracking peptide-based interventions for aging may find the discussed mechanisms relevant to emerging therapeutic targets.

Fight AgingJuly 26, 2026
5 min read
ResearchHigh

GLP-1s and Alcohol Use Disorder; No Luck With Gonorrhea Vaccine

Emerging research into GLP-1 receptor agonists continues to expand beyond metabolic indications, with new discussion focusing on their potential role in treating alcohol use disorder. The TTHealthWatch podcast hosted by Texas Tech and Johns Hopkins Medicine physicians examines the latest evidence surrounding these applications. This growing body of research underscores the broadening therapeutic profile of GLP-1 class peptides beyond weight loss and diabetes management.

GLP-1SemaglutideTirzepatide
MedPage TodayJuly 25, 2026
4 min read
RegulatoryMedium

A new, separate outbreak of the diarrhea-causing parasite

STAT News references a development characterized as a win for peptide proponents within its health news roundup, suggesting a favorable regulatory or policy outcome for the peptide therapy community. While the primary focus of the article is an unrelated public health outbreak, the inclusion of peptide news signals continued mainstream media attention to the peptide compounding landscape. Further details on the specific peptide regulatory development are expected to emerge in subsequent reporting.

STAT NewsJuly 24, 2026
3 min read
RegulatoryHigh

STAT+: Fatal gene-editing trial in China raises ethics and oversight questions

Amid broader biotech news, STAT News reports a notable regulatory development described as a win for peptide compounds, signaling a potentially favorable shift in the compounding and peptide therapy landscape. The mention of a Sanofi insulin pen supply shortage further underscores ongoing volatility in the pharmaceutical supply chain affecting peptide and biologic products. Industry stakeholders are watching closely as regulatory momentum around peptide compounds continues to evolve.

STAT NewsJuly 24, 2026
4 min read
Clinical TrialsHigh

Study Links GLP-1s to Lower Risk of Fragility Fractures in Diabetes Patients

A large target trial emulation study has found that initiating GLP-1 receptor agonist therapy for type 2 diabetes is associated with a meaningfully reduced risk of fragility fractures, including hip and vertebral fractures, in adults aged 50 and older. The findings add to the growing body of evidence supporting skeletal benefits of GLP-1 based therapies beyond glycemic control. This research may influence prescribing considerations for older diabetic patients at elevated fracture risk.

GLP-1SemaglutideTirzepatide
MedPage TodayJuly 25, 2026
4 min read
IndustryMedium

What Are Compounders Commonly Adding to GLP-1 Drugs?

A clinical quiz from MedPage Today examines what additives and adjunct compounds are frequently combined with GLP-1 receptor agonists by compounding pharmacies, reflecting growing industry and regulatory interest in this practice. The quiz format underscores how mainstream knowledge of GLP-1 compounding practices has become among healthcare professionals. Understanding these additions is increasingly relevant as regulators scrutinize the safety and consistency of compounded GLP-1 formulations.

GLP-1SemaglutideTirzepatide
MedPage TodayJuly 24, 2026
3 min read
RegulatoryCritical

FDA advisory panel narrowly rejects compounding of one peptide, backs two others

An FDA advisory panel voted to support compounding access for Epitalon and one additional peptide while narrowly rejecting compounding rights for Emideltide, drawing a clear regulatory line between approved and non-approved compounds. The split decision highlights the nuanced, case-by-case approach regulators are applying to the growing peptide compounding landscape. Health and Human Services Secretary Robert F. Kennedy Jr. has publicly endorsed peptide therapies, adding a political dimension to the ongoing regulatory debate.

EpitalonEmideltide
STAT NewsJuly 24, 2026
5 min read
RegulatoryCritical

FDA Panel Finds a Peptide It Doesn't Like

An FDA advisory panel continued its review of peptide compounding restrictions, recommending loosened rules for the majority of peptides examined while expressing reservations about at least one compound flagged by agency scientists. The deliberations mark a significant moment for the compounding pharmacy industry and peptide therapy access, as federal regulators weigh safety data against patient demand. The panel's recommendations could reshape which peptides remain available through compounding channels going forward.

MedPage TodayJuly 24, 2026
5 min read
RegulatoryCritical

FDA panel backs easier access to peptides

An FDA advisory committee has voted in favor of allowing specialized compounding pharmacies to produce popular peptide therapies, overriding the recommendations of the agency's own scientific staff. The panel's decision marks a pivotal moment for the peptide therapy industry, which has faced mounting regulatory pressure over compounding access in recent years. The vote is viewed as a landmark win by peptide therapy advocates and compounding pharmacy stakeholders who have long argued for patient access protections.

NPR HealthJuly 24, 2026
3 min read
RegulatoryCritical

STAT+: Pharmalittle: We're reading about an FDA panel and peptides, a Merck license for an HIV pill, and more

An FDA advisory panel has recommended that compounding pharmacies be permitted to produce four specific peptide drugs, representing a significant regulatory development for the peptide therapy community. The recommendation runs counter to guidance from FDA scientists who had advised against allowing such compounding access. If adopted, the decision could substantially expand patient access to peptide compounds through specialized pharmacy channels.

STAT NewsJuly 24, 2026
4 min read
IndustryHigh

Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal

Novo Nordisk has filed a motion in a New Jersey federal court seeking a temporary injunction against Eli Lilly advertising campaigns related to GLP-1 therapies, escalating the legal and competitive tensions between the two dominant players in the weight loss drug market. The dispute centers on claims made in Lilly promotional materials that Novo contends are misleading to consumers and healthcare providers. The legal battle reflects the intensifying commercial rivalry over GLP-1 receptor agonist market share as demand continues to surge.

GLP-1SemaglutideTirzepatide
Endpoints NewsJuly 24, 2026
4 min read
RegulatoryCritical

NYC Woman Dead After Receiving a "Longevity Infusion"

A New York City woman has died following an intravenous NAD+ infusion administered in a longevity medicine context, raising serious concerns about patient safety in unregulated wellness settings. Experts consulted in the report emphasize that the incident highlights the dangers of administering unproven intravenous therapies without adequate clinical oversight. The case is expected to intensify regulatory scrutiny around longevity infusion clinics and related compounding practices.

NAD+
Lifespan.ioJuly 24, 2026
4 min read
RegulatoryCritical

FDA adcomm votes in favor of lifting restrictions on popular wellness peptide BPC-157

An FDA advisory committee has recommended expanding compounding pharmacy access to BPC-157, a peptide popular among health and wellness enthusiasts for its purported muscle repair and injury healing properties. The recommendation positions compounding pharmacies for potentially significant commercial opportunity if the FDA adopts the panel's guidance. The development is being closely watched by the peptide therapy industry as a bellwether for regulatory treatment of similar compounds.

BPC-157
Endpoints NewsJuly 23, 2026
4 min read
RegulatoryCritical

STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides

The FDA advisory panel issued a narrow recommendation to permit compounding pharmacies to produce BPC-157 and KPV, two peptides that have gained popularity in health and wellness circles but lack formal regulatory approval. The vote marks a notable political and regulatory moment, reflecting the influence of the current HHS leadership on FDA advisory processes. Industry observers anticipate the decision could open the door for broader compounding access to other unapproved peptides.

BPC-157KPV
STAT NewsJuly 23, 2026
5 min read
RegulatoryCritical

FDA Panel Narrowly Backs Lifting Restrictions on Peptides Backed by RFK Jr.

An FDA advisory committee voted to remove compounding restrictions on BPC-157 and KPV, two peptides widely used in the wellness community despite limited clinical evidence supporting their safety and efficacy. The narrow vote represents a significant regulatory shift that could expand compounding pharmacy access to these substances. The decision aligns with broader policy positions advocated by Health and Human Services Secretary RFK Jr. and may set a precedent for how unapproved peptides are treated under federal compounding guidelines.

BPC-157KPV
MedPage TodayJuly 23, 2026
5 min read
RegulatoryCritical

STAT+: FDA staff and peptide enthusiasts set to clash at advisory panel

FDA advisory committee members are set to weigh whether permitting compounding pharmacies to offer peptide therapies represents a safer alternative to the unregulated gray-market supply currently in widespread use. Agency staff are expected to push back against broader access on the basis of limited clinical evidence, while patient advocates and practitioners will argue that regulated compounding offers a meaningful harm reduction pathway. The panel outcome is likely to set the tone for FDA peptide policy well into the coming years.

BPC-157TB-500EpithalonSelankSemaxCJC-1295Ipamorelin
STAT NewsJuly 23, 2026
5 min read
RegulatoryCritical

FDA panel considers easing peptide restrictions

An FDA advisory panel is reviewing evidence for seven distinct peptide compounds with the potential to ease current access restrictions and allow compounding pharmacies to provide these therapies through regulated pathways. A favorable outcome from the panel would mark a significant policy shift affecting how peptides are manufactured, distributed, and prescribed across the United States. The deliberations reflect growing demand from patients and practitioners for legitimate access to peptide therapies that currently exist in a largely unregulated gray market.

BPC-157TB-500EpithalonSelankSemax
NPR HealthJuly 23, 2026
4 min read
Clinical TrialsHigh

STAT+: New data on Eli Lilly's 'triple-G' drug leave open questions on heart benefit

Phase 3 cardiovascular data for retatrutide showed no statistically significant reduction in death, heart attack, or stroke among participants, a finding that distinguishes it from semaglutide and other GLP-1 agents with established cardiovascular outcome trial success. The absence of a confirmed cardiovascular benefit may affect labeling, prescribing patterns, and payer coverage decisions if the drug receives approval. Analysts and clinicians are reassessing how the triple agonist mechanism translates to long-term cardiometabolic protection.

RetatrutideGLP-1GIPGlucagon
STAT NewsJuly 23, 2026
5 min read
Clinical TrialsCritical

Lilly's triple agonist heads to regulators after two more Phase 3 obesity wins

Eli Lilly announced plans to file retatrutide for regulatory approval early next year, following two additional successful Phase 3 trial outcomes that demonstrated the compound's industry-leading weight loss efficacy. Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, has produced some of the most powerful weight reduction results observed in late-stage obesity trials to date. The filing will position it as a next-generation successor in the rapidly expanding GLP-1 receptor agonist therapeutic class.

RetatrutideGLP-1GIPGlucagon
Endpoints NewsJuly 23, 2026
5 min read
RegulatoryCritical

Expect a clash at today's FDA peptide panel

An FDA advisory panel is convening to evaluate evidence on peptide compounds, with significant disagreement anticipated between agency staff and advocates for broader peptide access. The panel's decisions could determine whether certain peptides remain restricted or become available through regulated compounding channels. The meeting represents one of the most consequential regulatory moments for the peptide therapy community in recent years.

STAT NewsJuly 23, 2026
3 min read
Clinical TrialsHigh

STAT+: Pharmalittle: We're reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more

New data from Eli Lilly's retatrutide trial in patients with heart disease failed to demonstrate a statistically significant reduction in major cardiovascular events, leaving a critical efficacy question unanswered ahead of the drug's anticipated regulatory filing. The findings introduce uncertainty about retatrutide's cardiovascular profile compared to other approved GLP-1 class agents that have demonstrated cardioprotective benefits. Regulators and prescribers are expected to scrutinize these results closely as the triple agonist moves toward submission.

RetatrutideGLP-1GIPGlucagon
STAT NewsJuly 23, 2026
4 min read
RegulatoryHigh

A father's mission to save his daughter, and allegations on telehealth GLP-1 prescribing

Allegations of improper telehealth prescribing practices for GLP-1 medications have surfaced, drawing attention to compliance and ethical standards among digital health providers in the weight loss space. The report involves LifeMD and raises questions about the oversight of GLP-1 prescribing through telehealth platforms competing with established pharmaceutical players such as Novo Nordisk and Eli Lilly. The story highlights the ongoing tension between expanding patient access and maintaining prescribing integrity in the GLP-1 market.

GLP-1SemaglutideTirzepatide
STAT NewsJuly 23, 2026
4 min read
RegulatoryCritical

FDA panel confronting peptide controversy

The FDA is convening an advisory panel to evaluate the regulatory status of multiple peptides, a move that could significantly reshape access to compounded peptide therapies. The panel's deliberations arrive alongside new approval decisions and emerging data on Eli Lilly's triple receptor agonist retatrutide. The outcome of the peptide review is anticipated to have broad implications for compounding pharmacies and the peptide therapy industry.

RetatrutideGLP-1GIP
STAT NewsJuly 23, 2026
3 min read
RegulatoryHigh

Death at Lifestyle Clinic; Consequences for J6 Doc; $4.7M Kickback Settlement

A 27-year-old woman died following an NAD+ injection administered by an unlicensed physician at a Bronx lifestyle clinic, raising serious concerns about the safety and oversight of intravenous peptide and NAD+ therapies outside regulated medical settings. The incident underscores the risks associated with unregulated wellness and longevity clinics offering injectable compounds without proper licensure. This case is expected to intensify regulatory scrutiny of compounding and lifestyle medicine practices nationwide.

NAD+
MedPage TodayJuly 23, 2026
4 min read
ResearchHigh

GLP-1s for Addiction; DEA's Ketamine Crackdown; ADHD and Social Media

Emerging retrospective data indicate that GLP-1 receptor agonists are associated with a reduced risk of alcohol-related hospitalization in adults with alcohol addiction, broadening the potential therapeutic applications of this drug class beyond metabolic disease. Additional findings from BMJ Open suggest GLP-1 drugs prescribed for obesity may carry further behavioral health benefits. These results are prompting renewed interest in the neurological and psychiatric mechanisms through which GLP-1 receptor agonists may modulate reward pathways.

GLP-1
MedPage TodayJuly 22, 2026
5 min read
ResearchHigh

New Study Links GLP-1s to Hair Loss

A target trial emulation study has found that adults with type 2 diabetes using GLP-1 receptor agonists face an increased risk of clinically recorded hair loss compared to those on other antidiabetic medications. The findings add to the growing body of literature examining the side effect profile of this widely prescribed drug class. Clinicians and patients considering GLP-1 therapy may need to weigh this emerging risk factor alongside the established metabolic benefits.

GLP-1
MedPage TodayJuly 22, 2026
4 min read
IndustryHigh

STAT+: Anthropic deepens work with rare disease drugs

Novo Nordisk has filed a lawsuit against Eli Lilly in a legal dispute centered on GLP-1 receptor agonist therapies, signaling intensifying competition in the blockbuster weight loss and diabetes drug market. The litigation highlights the growing commercial and intellectual property stakes surrounding GLP-1 class medications as multiple pharmaceutical giants vie for market dominance. This legal development could have meaningful implications for future GLP-1 drug development, pricing, and market access.

GLP-1SemaglutideTirzepatide
STAT NewsJuly 21, 2026
4 min read
RegulatoryCritical

Peptides get their regulatory close-up

An FDA advisory panel is convening to evaluate whether compounding pharmacies should be permitted to produce select wellness peptides, marking a pivotal regulatory moment for the peptide therapy industry. The outcome of these recommendations could determine the legal availability of widely used compounded peptides for consumers and clinicians alike. This meeting represents one of the most significant regulatory reviews of peptide compounding in recent years.

NPR HealthJuly 22, 2026
4 min read
IndustryHigh

GLP-1 Maker Sued Over Ads; Vaginal Estrogen; Melinda Gates Talks Perimenopause

Novo Nordisk initiated legal action against Eli Lilly over allegations of false advertising concerning comparative weight loss drug performance, drawing renewed attention to competitive claims within the GLP-1 therapeutic class. Separately, data highlighted in the roundup show that GLP-1 drug utilization surged 230 percent among adults with diabetes between 2017 and 2022, underscoring the rapid mainstream adoption of this peptide-based drug class. These developments reflect the intensifying commercial and regulatory scrutiny surrounding GLP-1 receptor agonists as the market continues to expand.

GLP-1SemaglutideTirzepatide
MedPage TodayJuly 21, 2026
4 min read
IndustryHigh

Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses

Novo Nordisk has filed a lawsuit against Eli Lilly, alleging that the competing drugmaker engaged in maliciously and deceptively false advertising related to comparative dosing claims for their respective GLP-1 weight loss medications. The legal dispute marks a significant escalation between the two dominant players in the obesity and diabetes drug market, where semaglutide and tirzepatide compete directly for market share. The outcome of this case could set important precedents for how GLP-1 receptor agonist manufacturers are permitted to characterize and compare clinical performance in direct advertising.

GLP-1SemaglutideTirzepatide
Endpoints NewsJuly 21, 2026
4 min read
IndustryHigh

STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls 'deceptive'

Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the company conducted a deceptive advertising campaign that relied on outdated clinical trial data to misrepresent the efficacy of its GLP-1 and obesity drug portfolio. The legal action underscores intensifying competitive tensions in the rapidly growing GLP-1 receptor agonist market, where both companies hold major product stakes. The case may set a precedent for how comparative efficacy claims are regulated and contested within the weight management and diabetes therapeutic space.

GLP-1SemaglutideTirzepatide
STAT NewsJuly 21, 2026
4 min read
RegulatoryCritical

Notes from a peptide meetup

An FDA advisory committee is set to weigh in on whether several popular peptides should be reclassified, marking a potentially pivotal moment for the peptide therapy landscape. A firsthand account from a recent industry meetup offers ground-level perspective on stakeholder sentiment and the regulatory stakes involved. The outcome of the advisory committee decision could have broad implications for compounding pharmacies and patients who rely on access to these compounds.

Endpoints NewsJuly 21, 2026
5 min read
RegulatoryCritical

Troubling Findings in Study of GLP-1 Compounders

A new study reveals that the compounded GLP-1 drug market remained active even after the resolution of semaglutide and tirzepatide shortages, raising significant safety and regulatory concerns. Researchers found that many compounding facilities continued operations while incorporating unapproved additives such as B vitamins, calling into question oversight standards. The findings highlight persistent gaps in compounding pharmacy regulation that may expose patients to unverified formulations of popular GLP-1 receptor agonists.

SemaglutideTirzepatideGLP-1
MedPage TodayJuly 20, 2026
5 min read
RegulatoryMedium

HHS vaccine committee quietly gets new charter

A recent health news roundup includes reporting on lax clinical oversight surrounding online GLP-1 prescriptions, raising questions about prescriber accountability in digital health settings. The coverage underscores growing concern among policymakers and clinicians about the adequacy of existing frameworks governing GLP-1 access through online platforms. These developments may foreshadow additional federal scrutiny of telehealth-based peptide therapy prescribing.

GLP-1
STAT NewsJuly 20, 2026
3 min read
RegulatoryHigh

STAT+: Pharmalittle: We're reading about a telehealth firm and patient safety, PBMs overcharging, and more

Former employees of telehealth company LifeMD have raised concerns that the company prioritized GLP-1 prescription volume over patient safety standards. The allegations highlight ongoing scrutiny of direct-to-consumer telehealth platforms operating in the rapidly expanding GLP-1 prescribing market. Regulatory and oversight pressure on telehealth-based peptide prescribing practices continues to intensify as patient safety questions mount.

GLP-1SemaglutideTirzepatide
STAT NewsJuly 20, 2026
4 min read
IndustryCritical

Samsung Bio to step into peptides in $1.8B buy for PolyPeptide

Samsung Biologics has announced a $1.8 billion cash acquisition of Swiss CDMO PolyPeptide, marking a major strategic expansion into peptide active pharmaceutical ingredient manufacturing. The deal signals growing global investment in peptide production infrastructure as demand for therapeutic peptides continues to accelerate. This transaction positions Samsung Biologics as a significant player in the peptide contract manufacturing sector alongside its existing large-molecule biologics capabilities.

Endpoints NewsJuly 20, 2026
4 min read
Clinical TrialsMedium

The Upside-Down World of the GLP-1 Bridge

A MedPage Today opinion piece highlights the growing clinical complexity surrounding GLP-1 receptor agonist therapy, particularly the challenges physicians face in managing patient access and continuity of care. The piece draws attention to systemic barriers within healthcare infrastructure that complicate GLP-1 prescribing and coverage decisions. The account underscores the increasing frontline relevance of GLP-1 therapies and the administrative burdens shaping their real-world adoption.

GLP-1
MedPage TodayJuly 18, 2026
4 min read
IndustryMedium

STAT+: Celcuity's breast cancer drug approved, its first

A recent biotech roundup highlights emerging developments in the weight loss drug space, including progress on non-GLP-1 mechanisms as alternatives to existing receptor agonist therapies. The piece touches on regulatory leadership shifts at CBER and their potential downstream implications for the broader biologics and peptide therapy landscape. Researchers and industry observers are watching closely as new obesity treatment modalities challenge the dominance of GLP-1 based compounds.

GLP-1
STAT NewsJuly 15, 2026
4 min read
IndustryMedium

STAT+: A new biotech startup tries to tackle obesity, but not in the way you might expect

A newly launched biotech startup is pursuing obesity treatment through a mechanism distinct from the GLP-1 receptor agonist pathway that has dominated the field in recent years. The approach signals growing interest in diversifying obesity drug development beyond the current generation of peptide-based therapies. If successful, this strategy could reshape the competitive landscape and offer alternatives for patients who do not respond to or tolerate existing GLP-1 treatments.

GLP-1
STAT NewsJuly 15, 2026
4 min read
ResearchHigh

New GLP-1 Concern; FDA Sued by Health Groups; Over 750 Dead in Ebola Outbreak

A preprint study has flagged potential signals of frailty in older adults taking tirzepatide for weight loss, raising new questions about the risk profile of GLP-1 receptor agonist therapies in senior populations. The findings add to ongoing regulatory and clinical scrutiny surrounding the long-term safety of widely prescribed peptide-based obesity treatments. Researchers and clinicians are calling for further investigation before broader use in elderly patients is recommended.

GLP-1Tirzepatide
MedPage TodayJuly 15, 2026
4 min read
IndustryHigh

Eli Lilly invests in Oura to support patients on GLP-1 drugs

Eli Lilly has made a strategic equity investment in wearable technology company Oura, signaling a growing industry focus on patient monitoring and adherence support for those on GLP-1 medications. The partnership reflects an emerging trend of pharmaceutical companies integrating digital health tools alongside peptide-based therapeutics to improve outcomes. This development underscores the expanding commercial ecosystem being built around GLP-1 receptor agonist therapies.

GLP-1Tirzepatide
Endpoints NewsJuly 15, 2026
3 min read
ResearchHigh

GLP-1s Good for Marriage Prospects? RFK Jr.'s Diabetes Ads Axed; CGMs for Toddlers

A working paper from the National Bureau of Economic Research found that GLP-1 receptor agonists did not meaningfully improve job or marriage outcomes for diabetes patients, adding nuance to the broader social impact narrative surrounding these widely used therapies. The report also projects that 57 million Americans will be classified as overweight by 2035, underscoring the continued public health urgency driving GLP-1 prescribing trends. Additional policy and device developments, including regulatory changes to continuous glucose monitors for pediatric populations, further illustrate the evolving landscape around metabolic disease management.

GLP-1
MedPage TodayJuly 14, 2026
5 min read
ResearchHigh

GLP-1s and Blinding Condition; Cyclosporiasis Source Found? Tylenol-Autism Lawsuits

A new cohort study has identified a potentially significant safety signal linking GLP-1 receptor agonist use in diabetes patients to an elevated risk of anterior ischemic optic neuropathy, a serious condition that can result in permanent vision loss. The findings add to the growing body of post-market surveillance data being scrutinized as GLP-1 therapies reach widespread clinical adoption. Clinicians and researchers are calling for further investigation to determine whether the association reflects a causal relationship or underlying confounding factors.

GLP-1
MedPage TodayJuly 14, 2026
5 min read
Clinical TrialsHigh

Study Dampens Hope for GLP-1s as Insulin Off-Ramp in Type 2 Diabetes

A target emulation trial examining veterans with type 2 diabetes found that adding a GLP-1 receptor agonist was not associated with a greater likelihood of discontinuing basal insulin therapy compared to other glucose-lowering agents. The findings challenge a widely held clinical assumption that GLP-1 receptor agonists could serve as a reliable pathway away from insulin dependence. This research carries meaningful implications for how clinicians position GLP-1 therapies within broader type 2 diabetes management protocols.

GLP-1
MedPage TodayJuly 13, 2026
4 min read
ResearchHigh

Study Compares GLP-1 Drugs on Their Benefits, Harms

A comprehensive systematic review and network meta-analysis of 262 randomized studies evaluated the comparative benefits and harms of GLP-1 receptor agonist drugs, revealing variable outcomes in weight loss and cardiovascular endpoints across the drug class. The findings highlight meaningful differences between individual agents in terms of efficacy and safety profiles, offering clinicians a more nuanced framework for prescribing decisions. Effects on patient quality of life remained less conclusive, pointing to a critical gap in the existing evidence base for this rapidly growing therapeutic category.

GLP-1SemaglutideTirzepatideLiraglutide
MedPage TodayJuly 10, 2026
5 min read
ResearchHigh

Newer Diabetes Drugs, Including GLP-1 Agonists, Tied to Autoimmunity Risk

A large-scale analysis of hundreds of thousands of patient records has identified differing risks for new-onset autoimmune conditions among users of newer antidiabetic medications, including GLP-1 receptor agonists. The findings add an important safety dimension to the growing body of research surrounding GLP-1 based therapies, which have seen rapid adoption for both diabetes management and weight loss. Clinicians and researchers are now calling for closer monitoring of autoimmune markers in patients initiating these drug classes.

GLP-1
MedPage TodayJuly 9, 2026
5 min read
ResearchHigh

GLP-1s and Liver Cancer Recurrence; IBS Acupuncture; Transmural Healing in Crohn's

A target trial emulation study published in Gut found that diabetic patients with hepatocellular carcinoma who initiated a GLP-1 receptor agonist experienced significantly longer time to cancer recurrence and improved overall survival compared to those on DPP-4 inhibitors. The findings add to a growing body of evidence suggesting GLP-1 receptor agonists may confer oncologic benefits beyond glycemic control. This research strengthens the case for broader investigation of GLP-1 therapies in metabolic and hepatic disease management.

GLP-1
MedPage TodayJuly 9, 2026
5 min read
RegulatoryHigh

STAT+: Europe will accelerate its review of RevMed's drug

A broader biotech news roundup includes a notable reference to concerns raised over Kailera's GLP-1 pill trial data, adding complexity to the competitive oral GLP-1 receptor agonist space as multiple candidates vie for regulatory approval. The European Medicines Agency's decision to accelerate review of another drug compound further reflects heightened regulatory engagement across novel therapeutic modalities. These developments collectively illustrate the fast-moving regulatory and clinical environment surrounding next-generation GLP-1 therapies.

GLP-1
STAT NewsJuly 8, 2026
4 min read
Clinical TrialsCritical

New weight loss pill beats oral Ozempic in major trial

A major clinical trial has demonstrated that orforglipron, a once-daily oral small molecule weight loss pill, outperformed oral semaglutide in both weight reduction and blood sugar control, representing a potentially significant shift in the GLP-1 therapeutic landscape. Unlike injectable formulations, orforglipron requires no refrigeration and carries no meal-timing restrictions, features that could substantially broaden global patient access. Its lower manufacturing cost further strengthens its competitive profile against existing GLP-1 receptor agonist therapies.

SemaglutideGLP-1orforglipron
ScienceDaily Sports MedJuly 8, 2026
4 min read